Endogenous morphine: Opening new doors for the treatment of pain and addiction

Expert Opinion on Biological Therapy

Volumn 5, Issue 7, 2005, Pages 893-906

  Pryor, Stephen C ^a   Zhu, Wei ^a   Cadet, Patrick ^a   Bianchi, Enrica ^b   Guarna, Massimo ^b   Stefano, George B ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Morphine; Mu opiate receptors; Neural tissues; Nitric oxide; Pain

Indexed keywords

3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; 7 NITROINDAZOLE; ARGININE; ATROPINE; DIZOCILPINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCERYL TRINITRATE; HYDROXYLAMINE; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOSORBIDE; LINSIDOMINE; MORPHINE; MU OPIATE RECEPTOR; N ACETYL S NITROSOPENICILLAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N(G) METHYLARGININE; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; NALOXONE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PROTEIN MU3 OPIATE RECEPTOR; RECEPTOR SUBTYPE; SILDENAFIL; UNCLASSIFIED DRUG;

ANALGESIA; ANTINOCICEPTION; BIOSYNTHESIS; CENTRAL NERVOUS SYSTEM; DIABETES MELLITUS; DNA SEQUENCE; DRUG DEPENDENCE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; HYPERALGESIA; IMMUNE SYSTEM; IMMUNOREACTIVITY; LIMBIC SYSTEM; MORPHINE ADDICTION; MORPHINE TOLERANCE; NERVOUS TISSUE; NOCICEPTION; NOCICEPTIVE STIMULATION; NONHUMAN; PAIN; PAIN THRESHOLD; PERIPHERAL NERVOUS SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SPINAL CORD; VASCULAR TISSUE;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; BASE SEQUENCE; BRAIN; CYCLIC AMP; CYCLIC GMP; DIABETES MELLITUS; DRUG TOLERANCE; ENZYME INHIBITORS; HUMANS; INJECTIONS, INTRAVENTRICULAR; MOLECULAR SEQUENCE DATA; MORPHINE; MORPHINE DEPENDENCE; NEURONS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PAIN; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 22744447360     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.7.893     Document Type: Review

References (148)

1. GARTHWAITE J, CHARLES SL, CHESS-WILLIAMS R: Endothelium-derived relaxing factor release on activation of NMDA receptors suggests a role as intracellular messenger in the brain. Nature (1988) 336:385-388.
2. IGNARRO LJ, LIPPTON H, EDWARDS JC et al.: Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J. Pharmacol. Exp. Ther. (1981) 218(3):739-749.
3. IGNARRO LJ: Signal transduction mechanisms involving nitric oxide. Biochem. Pharmacol. (1991) 41(4):485-490.
4. MONCADA S, HIGGS A, FURCHGOTT R: International Union of Pharmacology Nomenclature in Nitric Oxide Research. Pharmacol. Rev. (1997) 49(2):137-142.
5. STEFANO GB, GOUMON Y, BILFINGER TV, WELTERS I, CADET P: Basal nitric oxide limits immune, nervous and cardiovascular excitation: human endothelia express a mu opiate receptor. Prog. Neurobiol. (2000) 60:531-544.
6. BENZ D, CADET P, MANTIONE K, ZHU W, STEFANO GB: Tonal nitric oxide and health: a free radical and a scavenger of free radicals. Med. Sci. Monit. (2002) 8(1):1-4.
7. FORSTERMANN U, KLEINERT H: Nitric oxide synthase: expression and expressional control of the three isoforms. Naunyn Schmiedebergs Arch. Pharmacol. (1995) 352(4):351-364.
8. SCHMIDT HH, GAGNE GD, NAKANE M et al.: Mapping of neural nitric oxide synthase in the rat suggests frequent co-localization with NADPH diaphorase but not with soluble guanylyl cyclase, and novel paraneural functions for nitrinergic signal transduction. J. Histochem. Cytochem. (1992) 40(10):1439-1456.
9. OKUDA K, SAKURADA C, TAKAHASHI M, YAMADA T, SAKURADA T: Characterization of nociceptive responses and spinal releases of nitric oxide metabolites and glutamate evoked by different concentrations of formalin in rats. Pain (2001) 92(1-2):107-115.
10. DUN NJ, DUN SL, CHIBA T, FORSTERMANN U: Nitric oxide synthase- immunoreactive vagal afferent fibers in rat superior cervical ganglia. Neuroscience (1995) 65(1):231-239.
11. LAM HH, HANLEY DF, TRAPP BD et al.: Induction of spinal cord neuronal nitric oxide synthase (NOS) after formalin injection in the rat hind paw. Neurosci. Lett. (1996) 210(3):201-204.
12. TRAUB RJ, SOLODKIN A, MELLER ST, GEBHART GF: Spinal cord NADPH-diaphorase histochemical staining but not nitric oxide synthase immunoreactivity increases following carrageenan-produced hindpaw inflammation in the rat. Brain Res. (1994) 668(1-2):204-210.
13. FIALLOS-ESTRADA CE, KUMMER W, MAYER B et al.: Long-lasting increase of nitric oxide synthase immunoreactivity, NADPH-diaphorase reaction and c-JUN co-expression in rat dorsal root ganglion neurons following sciatic nerve transection. Neurosci. Lett. (1993) 150(2):169-173.
14. PRZEWLOCKI R, MACHELSKA H, PRZEWLOCKA B: Inhibition of nitric oxide synthase enhances morphine antinociception in the rat spinal cord. Life Sci. (1993) 53(1):L1-L5.
15. HALEY JE, DICKENSON AH, SCHACHTER M: Electrophysiological evidence for a role of nitric oxide in prolonged chemical nociception in the rat. Neuropharmacology (1992) 31(3):251-258.
16. DICKENSON A, HALEY J, SCHACHTER M, CHAPMAN V: Electrophysiological approaches to the study of bradykinin and nitric oxide in inflammatory pain. Agents Actions Suppl. (1992) 38(Pt2):358-365.
17. MOORE PK, BABBEDGE RC, WALLACE P, GAFFEN ZA, HART SL: 7-Nitro indazole, an inhibitor of nitric oxide synthase, exhibits anti-nociceptive activity in the mouse without increasing blood pressure. Br. J. Pharmacol. (1993) 108(2):296-297.
18. MALMBERG AB, YAKSH TL: Spinal nitric oxide synthesis inhibition blocks NMDA-induced thermal hyperalgesia and produces antinociception in the formalin test in rats. Pain (1993) 54(3):291-300.
19. INOUE T, MASHIMO T, SHIBUTA S, YOSHIYA I: Intrathecal administration of a new nitric oxide donor, NOC-18, produces acute thermal hyperalgesia in the rat. J. Neurol. Sci. (1997) 153(1):1-7.
20. MACHELSKA H, LABUZ D, PRZEWLOCKI R, PRZEWLOCKA B: Inhibition of nitric oxide synthase enhances antinociception mediated by mu, delta and kappa opioid receptors in acute and prolonged pain in the rat spinal cord. J. Pharmacol. Exp. Ther. (1997) 282(2):977-984.
21. ROCHE AK, COOK M, WILCOX GL, KAJANDER KC: A nitric oxide synthesis inhibitor (L-NAME) reduces licking behavior and Fos-labeling in the spinal cord of rats during formalin-induced inflammation. Pain (1996) 66(2-3):331-341.
22. HAO JX, XU XJ: Treatment of a chronic allodynia-like response in spinally injured rats: effects of systemically administered nitric oxide synthase inhibitors. Pain (1996) 66(2-3):313-319.
23. YONEHARA N, TAKEMURA M, YOSHIMURA M et al.: Nitric oxide in the rat spinal cord in Freund's adjuvant-induced hyperalgesia. Jpn. J. Pharmacol. (1997) 75(4):327-335.
24. BABBEDGE RC, HART SL, MOORE PK: Anti-nociceptive activity of nitric oxide synthase inhibitors in the mouse: dissociation between the effect of L-NAME and L-NMMA. J. Pharm. Pharmacol. (1993) 45(1):77-79.
25. MOORE PK, OLUYOMI AO, BABBEDGE RC, WALLACE P, HART SL: L-NG-nitro arginine methyl ester exhibits antinociceptive activity in the mouse. Br. J. Pharmacol. (1991) 102(1):198-202.
26. CODERRE TJ, YASHPAL K: Intracellular messengers contributing to persistent nociception and hyperalgesia induced by L-glutamate and substance P in the rat formalin pain model. Eur. J. Neurosci. (1994) 6(8):1328-1334.
27. GRANADOS-SOTO V, RUFINO MO, GOMES LOPES LD, FERREIRA SH: Evidence for the involvement of the nitric oxide-cGMP pathway in the antinociception of morphine in the formalin test. Eur. J. Pharmacol. (1997) 340(2-3):177-180.
28. ALEY KO, MCCARTER G, LEVINE JD: Nitric oxide signaling in pain and nociceptor sensitization in the rat. J. Neurosci. (1998) 18(17):7008-7014.
29. XU JY, PIEPER GM, TSENG LF: Activation of a NO-cyclic GMP system by NO donors potentiates beta-endorphin-induced antinociception in the mouse. Pain (1995) 63(3):377-383.
30. SHIBUTA S, MASHIMOTO T, OHARA A, ZHANG P, YOSHIYA I: Intracerebroventricular administration of a nitric oxide-releasing compound, NOC-18, produces thermal hyperalgesia in rats. Neurosci. Lett. (1995) 187(2):103-106.
31. MACHELSKA H, PRZEWLOCKI R, RADOMSKI MW, PRZEWLOCKA B: Differential effects of intrathecally and intracerebroventricularly administered nitric oxide donors on noxious mechanical and thermal stimulation. Pol. J. Pharmacol. (1998) 50(6):407-415.
32. KITTO KF, HALEY JE, WILCOX GL: Involvement of nitric oxide in spinally mediated hyperalgesia in the mouse. Neurosci. Lett. (1992) l48(1-2):1-5.
33. HOLTHUSEN H, ARNDT JO: Nitric oxide evokes pain in humans on intracutaneous injection. Neurosci. Lett. (1994) 165(1-2):71-74.
34. KINDGEN-MILLES D, ARNDT JO: Nitric oxide as a chemical link in the generation of pain from veins in humans. Pain (1996) 64(1):139-l42.
35. GARRY MG, RICHARDSON JD, HARGREAVES KM: Sodium nitroprusside evokes the release of immunoreactive calcitonin gene-related peptide and substance P from dorsal horn slices via nitric oxide-dependent and nitric oxide-independent mechanisms. J. Neurosci. (1994) 14(7):4329-4337.
36. BEIRITH A, SANTOS AR, CALIXTO JB: Mechanisms underlying the nociception and paw oedema caused by injection of glutamate into the mouse paw. Brain Res. (2002) 924(2):219-228.
37. DUARTE ID, FERREIRA SH: The molecular mechanism of central analgesia induced by morphine or carbachol and the L-arginine-nitric oxide-cGMP pathway. Eur. J. Pharmacol. (1992) 221(1):171-174.
38. DUARTE ID, DOS SANTOS IR, LORENZETTI BB, FERREIRA SH: Analgesia by direct antagonism of nociceptor sensitization involves the arginine-nitric oxide-cGMP pathway. Eur. J. Pharmacol. (1992) 217(2-3):225-227.
39. FERREIRA SH, DUARTE ID, LORENZETTI BB: The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release. Eur. J. Pharmacol. (1991) 201(1):121-122.
40. SOUSA AM, PRADO WA: The dual effect of a nitric oxide donor in nociception. Brain Res. (2001) 897(1-2):9-19.
41. PRADO WA, SCHIAVON VF, CUNHA FQ: Dual effect of local application of nitric oxide donors in a model of incision pain in rats. Eur. J. Pharmacol. (2002) 441(1-2):57-65.
42. HARIMA A, SHIMIZU H, TAKAGI H: Analgesic effect of L-arginine in patients with persistent pain. Eur. Neuropsychopharmacol. (1991) 1(4):529-533.
43. TAKAGI H: [Physiological and pharmacological actions of a neuroactive dipeptide, kyotorphin, and its precursor, L-arginine, and clinical application]. Nippon Yakurigaku Zasshi (1990) 96(3):85-96.
44. BERRAZUETA JR, SALAS E, OCHOTECO A, POVEDA JJ, SANCHEZ DE VEGA MJ: [The peripheral analgesic action of the exogenous nitric oxide donor: nitroglycerin. A placebo-controlled study of the transdermal action of nitroglycerin on pain sensitivity in the forearm]. Rev. Esp. Cardiol. (1993) 46(1):10-14.
45. LAURETTI GR, PEREZ MV, REIS MP, PEREIRA NL: Double-blind evaluation of transdermal nitroglycerine as adjuvant to oral morphine for cancer pain management. J. Clin. Anesth. (2002) 14(2):83-86.
46. BERRAZUETA JR, FLEITAS M, SALAS E et al.: Local transdermal glyceryl trinitrate has an antiinflammatory action on thrombophlebitis induced by sclerosis of leg varicose veins. Angiology (1994) 45(5):347-351.
47. PITTROF R, LEES C, THOMPSON C et al.: Crossover study of glyceryl trinitrate patches for controlling pain in women with severe dysmenorrhoea. Br. Med. J. (1996) 312(7035):884.
48. ZHUO M, MELLER ST, GEBHART GF: Endogenous nitric oxide is required for tonic cholinergic inhibition of spinal mechanical transmission. Pain (1993) 54(1):71-78.
49. JAIN NK, PATIL CS, SINGH A, KULKARNI SK: Sildenafil-induced peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Brain Res. (2001) 909(1-2):170-178.
50. KAWABATA A, MANABE S, MANABE Y, TAKAGI H: Effect of topical administration of L-arginine on formalin-induced nociception in the mouse: a dual role of peripherally formed NO in pain modulation. Br. J. Pharmacol. (1994) 112(2):547-550.
51. SOARES AC, LEITE R, TATSUO MA, DUARTE ID: Activation of ATP-sensitive K(+) channels: mechanism of peripheral antinociceptive action of the nitric oxide donor, sodium nitroprusside. Eur. J. Pharmacol. (2000) 400(1):67-71.
52. STEFANO GB, NEENAN K, CADET P, MAGAZINE HI, BILFINGER TV: Ischemic preconditioning - an opiate constitutive nitric oxide molecular hypothesis. Med. Sci. Monit. (2001) 7(6):1357-1375.
53. DUARTE ID, FERREIRA SH: L-NAME causes antinociception by stimulation of the arginine-NO-cGMP pathway. Mediators. Inflamm. (2000) 9(1):25-30.
54. JAIN NK, PATIL CS, SINGH A, KULKARNI SK: Sildenafil, a phosphodiesterase-5 inhibitor, enhances the antinociceptive effect of morphine. Pharmacology (2003) 67(3): 150-156.
55. STEFANO GB, FRICCHIONE GL, ESCH T: Pain, immunity, opiate and opioid compounds and health. Med. Sci. Monit. (2005) 11(5):MS47-MS53.
56. GINTZLER AR, LEVY A, SPECTOR S: Antibodies as a means of isolating and characterizing biologically active substances: Presence of a non-peptide morphine-like compound in the central nervous system. Proc. Natl. Acad. Sci. USA (1976) 73:2132-2136.
57. GINTZLER AR, GERSHON MD, SPECTOR S: A nonpeptide morphine-like compound: immunocytochemical localization in the mouse brain. Science (1978) 199:447-448.
58. KILLIAN AK, SCHUSTER CR, HOUSE JT et al.: A non-peptide morphine-like compound from brain. Life Sci. (1981) 28:811-817.
59. ESCH T, GUARNA M, BIANCHI E, ZHU W, STEFANO GB: Commonalities in the central nervous system's involvement with complementary medical therapies: Limbic morphinergic processes. Med. Sci. Monit. (2004) 10(6):MS6-MS17.
60. GOLDSTEIN A, BARRETT RW, JAMES IF et al.: Morphine and other opiates from beef brain and adrenal. Proc. Natl. Acad. Sci. USA (1985) 82:5203-5207.
61. DONNERER J, OKA K, BROSSI A, RICE KC, SPECTOR S: Presence and formation of codeine and morphine in the rat. Proc. Natl. Acad. Sci. USA (1986) 83:4566-4567.
62. CARDINALE GJ, DONNERER J, FINCK AD et al.: Morphine and codeine are endogenous components of human cerebrospinal fluid. Life Sci. (1987) 40:301-306.
63. DONNERER J, CARDINALE G, COFFEY J et al.: Chemical characterization and regulation of endogenous morphine and codeine in the rat. J. Pharmacol. Exp. Ther. (1987) 242:583-587.
64. STEFANO GB, DIGENIS A, SPECTOR S et al.: Opiatelike substances in an invertebrate, a novel opiate receptor on invertebrate and human immunocytes, and a role in immunosuppression. Proc. Natl. Acad. Sci. USA (1993) 90:11099-11103.
65. MUNJAL ID, MINNA JD, MANNECKJEE R, BIECK P, SPECTOR S: Possible role of endogenous morphine and codeine on growth regulation of lung tissue. Life Sci. (1996) 57(5):517-521.
66. BILFINGER TV, HARTMAN A, LIU Y, MAGAZINE HI, STEFANO GB: Cryopreserved veins used for myocardial revascularization: possible mechanism for their increased failure. Ann. Thorac. Surg. (1997) 63:1063-1069.
67. GUARNA M, NERI C, PETRIOLI F, BIANCHI E: Potassium-induced release of endogenous morphine form rat brain slices. J. Neurochem. (1998) 70(1):147-152.
68. GOUMON Y, STEFANO GB: Identification of morphine in the rat adrenal gland. Mol. Brain Res. (2000) 77:267-269.
69. GOUMON Y, WEEKS BS, CADET P, STEFANO GB: Identification of morphine in the adrenal medullary chromaffin PC-12 cell line. Mol. Brain Res. (2000) 81:177-180.
70. GOUMON Y, BOURET S, CASARES F et al.: Lipopolysaccharide increases endogenous morphine levels in rat brain. Neurosci. Lett. (2000) 293(2):135-138.
71. NERI C, GUARNA M, BIANCHI E et al.: Endogenous morphine and codeine in the brain of non-human primate. Med. Sci. Monit. (2004) 10(6):MS1-MS5.
72. ZHU W, MA Y, CADET P et al.: Presence of reticuline in rat brain: A pathway for morphine biosynthesis. Mol. Brain Res. (2003) 117(1):83-90.
73. KODAIRA H, LISTEK CA, JARDINE I, ARIMURA A, SPECTOR S: Identification of the convusant opiate thebaine in the mammalian brain. Proc. Natl. Acad. Sci. USA (1989) 86:716-719.
74. EPPLE A, NAVARRO I, HORAK P, SPECTOR S: Endogenous morphine and codeine: release by the chromaffin cells of the eel. Life Sci. (1993) 52(16):PL117-PL121.
75. HOFMANN U, SEEFRIED S, SCHWEIZER E et al.: Highly sensitive gas chromatographic-tandem mass spectrometric method for the determination of morphine and codeine in serum and urine in the femtomolar range. J. Chromatogr. B Biomed. Sci. Appl. (1999) 727(1-2):81-88.
76. ZHU W, MANTIONE KJ, STEFANO GB: In vivo and in vitro L-DOPA exposure increases ganglionic morphine levels. Med. Sci. Monit. (2005) 11(5):MS1-MS5.
77. WEITZ CJ, FAULL KF, GOLDSTEIN A: Synthesis of the skeleton of the morphine molecule by mammalian liver. Nature (1987) 330(6149):674-677.
78. KODAIRA H, SPECTOR S: Transformation of thebaine to oripavine, codeine, and morphine by rat liver, kidney, and brain microsomes. Proc. Natl Acad. Sci. USA (1988) 85(4):1267-1271.
79. POEAKNAPO C, SCHMIDT J, BRANDSCH M, DRAGER B, ZENK MH: Endogenous formation of morphine in human cells. Proc. Natl. Acad. Sci. USA (2004) 101(39):14091-14096.
80. ZHU W, MANTIONE KJ, STEFANO GB: Reticuline exposure to invertebrate Ganglia increases endogenous morphine levels. Neuro. Endocrinol. Lett. (2004) 25(5):323-330.
81. GOUMON Y, CASARES F, PRYOR S et al.: Ascaris suum, an internal parasite, produces morphine. J. Immunol. (2000) 165(1):339-343.
82. BIANCHI E, ALESSANDRINI C, GUARNA M, TAGLIAMONTE A: Endogenous codeine and morphine are stored in specific brain neurons. Brain Res. (1993) 627(2):210-215.
83. BIANCHI E, GUARNA M, TAGLIAMONTE A: Immunocytochemical localization of endogenous codeine and morphine. Adv. Neuroimmunol. (1994) 4:83-92.
84. STEFANO GB, GOUMON Y, CASARES F et al.: Endogenous morphine. Trends Neurosci. (2000) 9:436-442.
85. STEFANO GB, HALL B, MAKMAN MH, DVORKIN B: Opioid inhibition of dopamine release from nervous tissue of Mytilus edulis and Octopus bimaculatus. Science (1981) 213(4510):928-930.
86. CADET P, MANTIONE KJ, STEFANO GB: Molecular identification and functional expression of mu3, a novel alternatively spliced variant of the human mu opiate receptor gene. J. Immunol. (2003) 170(10):5118-5123.
87. SPECTOR S, MUNJAL I, SCHMIDT DE: Endogenous morphine and codeine. Possible role as endogenous anticonvulsants. Brain Res. (2001) 915(2):155-160.
88. ZHU W, MA Y, BELL A et al.: Presence of morphine in rat amygdala: evidence for the 3 opiate receptor subtype via nitric oxide release in limbic structures. Med. Sci. Monit. (2004) 10(12):BR433-BR439.
89. GUARNA M, BIANCHI E, BARTOLINI A et al.: Endogenous morphine modulates acute thermonociception in mice. J. Neurochem. (2002) 80(2):271-277.
90. IZQUIERDO I: Effect of beta-endorphin and naloxone on acquisition, memory, and retrieval of shuttle avoidance and habituation learning in rats. Psychopharmacology (Berl.) (1980) 69(1):111-115.
91. BRAIDA D, GORI E, SALA M: Relationship between morphine and etonitazene-induced working memory impairment and analgesia. Eur. J. Pharmacol. (1994) 271(2-3):497-504.
92. GUARNA M, GHELARDINI C, GALEOTTI N et al.: Effects of endogenous morphine deprivation on memory retention of passive avoidance learning in mice. Int. J. Neuropsychopharmacol. (2004) 7(3):311-319.
93. STEFANO GB, SCHARRER B, SMITH EM et al.: Opioid and opiate immunoregulatory processes. Crit. Rev. Immunol. (1996) 16(2):109-144.
94. STEFANO GB: Autoimmunovascular regulation: morphine and anandamide stimulated nitric oxide release. J. Neuroimmunol. (1998) 83:70-76.
95. STEFANO GB, ZHU W, CADET P, MANTIONE K: Morphine enhances nitric oxide release in the mammalian gastrointestinal tract via the μ3 opiate receptor subtype: a hormonal role for endogenous morphine. J. Physiol. Pharmacol. (2004) 55(1 Pt 2):279-288.
96. MANTIONE KJ, STEFANO GB: A sub-nanomolar real-time nitric oxide probe: in vivo nitric oxide release in heart. Med. Sci. Monit. (2004) 10(4):MT47-MT49.
97. XU JY, TSENG LF: Nitric oxide cyclic guanosine monophosphate system in the spinal cord differentially modulates intracerebroventricularly administered morphine and beta-endorphin-induced antinociception in the mouse. J. Pharmacol. Exp. Ther. (1995) 274(1):8-16.
98. PASTERNAK GW, KOLESNIKOV YA, BABEY AM: Perspectives on the N-methyl-D-aspartate/nitric oxide cascade and opioid tolerance. Neuropsychopharmacology (1995) 13(4):309-313.
99. OZEK M, URESIN Y, GUNGOR M: Comparison of the effects of specific and nonspecific inhibition of nitric oxide synthase on morphine analgesia, tolerance and dependence in mice. Life Sci. (2003) 72(17):1943-1951.
100. WATANABE C, OKUDA K, SAKURADA C et al.: Evidence that nitric oxide-glutamate cascade modulates spinal antinociceptive effect of morphine: a behavioural and microdialysis study in rats. Brain Res. (2003) 990(1-2):77-86.
101. FERREIRA SH, NAKAMURA M: II - Prostaglandin hyperalgesia: the peripheral analgesic activity of morphine, enkephalins and opioid antagonists. Prostaglandins (1979) 18(2):191-200.
102. MOLINA N, VETTORE O, LORENZETTI BB, FERREIRA SH: The peripheral analgesic effect of morphine, codeine, pentazocine and d-propoxyphene. Braz. J. Med. Biol. Res. (1983) 16(4):345-352.
103. FERREIRA SH, MOLINA N, VETTORE O: Prostaglandin hyperalgesia, V: a peripheral analgesic receptor for opiates. Prostaglandins (1982) 23(1):53-60.
104. KOLESNIKOV YA, JAIN S, WILSON R, PASTERNAK GW: Peripheral morphine analgesia: synergy with central sites and a target of morphine tolerance. J. Pharmacol. Exp. Ther. (1996) 279(2):502-506.
105. RODRIGUES AR, DUARTE ID: The peripheral antinociceptive effect induced by morphine is associated with ATP-sensitive K(+) channels. Br. J. Pharmacol. (2000) 129(1):110-114.
106. BHARGAVA HN: Diversity of agents that modify opioid tolerance, physical dependence, abstinence syndrome, and self-administrative behavior. Pharmacol. Rev. (1994) 46(3):293-324.
107. FRICCHIONE G, STEFANO GB: Placebo neurosystems: nitric oxide, morphine and the dopamine brain reward and motivation circuitries. Med. Sci. Monit. (2005) 11(5):MS54-MS65.
108. DAMBISYA YM, LEE TL: Role of nitric oxide in the induction and expression of morphine tolerance and dependence in mice. Br. J. Pharmacol. (1996) 117(5):914-918.
109. ELLIOTT K, MINAMI N, KOLESNIKOV YA, PASTERNAK GW, INTURRISI CE: The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain (1994) 56(1):69-75.
110. KOLESNIKOV YA, PICK CG, PASTERNAK GW: NG-nitro-L-arginine prevents morphine tolerance. Eur. J Pharmacol. (1992) 221(2-3):399-400.
111. CONTRERAS E, GERMANY A, GONZALEZ P, NORRIS B: Influence of opiate tolerance and calcium channel antagonists on the antinociceptive effects of L-arginine and NG-nitro L-arginine. Gen. Pharmacol. (1997) 28(3):443-448.
112. ADAMS ML, KALICKI JM, MEYER ER, CICERO TJ: Inhibition of the morphine withdrawal syndrome by a nitric oxide synthase inhibitor, NG-nitro-L-arginine methyl ester. Life Sci. (1993) 52(22):L245-L249.
113. RAGHAVENDRA V, KULKARNI SK: Possible mechanisms of action in melatonin reversal of morphine tolerance and dependence in mice. Eur. J. Pharmacol. (2000) 409(3):279-289.
114. MAJEED NH, PRZEWLOCKA B, MACHELSKA H, PRZEWLOCKI R: Inhibition of nitric oxide synthase attenuates the development of morphine tolerance and dependence in mice. Neuropharmacol. (1994) 33:189.
115. BHARGAVA HN: Attenuation of tolerance to, and physical dependence on, morphine in the rat by inhibition of nitric oxide synthase. Gen. Pharmacol. (1995) 26(5):1049-1053.
116. MEDVEDEV IO, DRAVOLINA OA, BESPALOVAY: Differential effects of nitric oxide synthase inhibitor, 7-nitroindazole, on discriminative stimulus and somatic effects of naloxone in morphine-dependent rats. Eur. J. Pharmacol. (1999) 377(2-3):183-186.
117. VAUPEL DB, KIMES AS, LONDON ED: Nitric oxide synthase inhibitors. Preclinical studies of potential use for the treatment of opioid withdrawal. Neuropsychopharmacol. (1995) 13(4):315-322.
118. PATAKI I, TELEGDY G: Further evidence that nitric oxide modifies acute and chronic morphine actions in mice. Eur. J. Pharmacol. (1998) 357(2-3):157-162.
119. VAUPEL DB, KIMES AS, LONDON ED: Further in vivo studies on attenuating morphine withdrawal: isoform-selective nitric oxide synthase inhibitors differ in efficacy. Eur. J. Pharmacol. (1997) 324(1):11-20.
120. BHARGAVA HN, BIAN JT, KUMAR S: Mechanism of attenuation of morphine antinociception by chronic treatment with L-arginine. J. Pharmacol. Exp. Ther. (1997) 281(2):707-712.
121. KOLESNIKOV YA, PAN YX, BABEY AM et al.: Functionally differentiating two neuronal nitric oxide synthase isoforms through antisense mapping: evidence for opposing NO actions on morphine analgesia and tolerance. Proc. Natl. Acad. Sci. USA (1997) 94(15):8220-8225.
122. MAO J, MAYER DJ: Spinal cord neuroplasticity following repeated opioid exposure and its relation to pathological pain. Ann. NY Acad. Sci. (2001) 933:175-184.
123. MAO J, PRICE DD, MAYER DJ: Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain (1995) 61(3):353-364.
124. SUGIMOTO T, BENNETT GJ, KAJANDER KC: Strychnine-enhanced transsynaptic degeneration of dorsal horn neurons in rats with an experimental painful peripheral neuropathy. Neurosci. Lett. (1989) 98(2):139-143.
125. MAYER DJ, MAO J, HOLT J, PRICE DD: Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc. Natl. Acad. Sci. USA (1999) 96(14):7731-7736.
126. KAMEI J, AOKI T, HITOSUGI H, IWAMOTO Y, KASUYA Y: Effects of morphine on responses of nociceptive ventrobasal thalamic neurons in diabetic rats. Jpn. J. Pharmacol. (1992) 60(2):133-140.
127. KAMEI J, OHSAWA M, MISAWA M, NAGASE H, KASUYA Y: Effects of diabetes on the morphine-induced Straub tail reaction in mice. Neurosci. Lett. (1994) 178(1):66-68.
128. KAMEI J, KAWASHIMA N, SUZUKI T, MISAWA M, KASUYA Y: The effects of cyclosporine on morphine-induced antinociception in diabetic mice. Neurosci. Lett. (1993) 158(2):213-216.
129. DENG W, THIEL B, TANNENBAUM CS, HAMILTON TA, STUEHR DJ: Synergistic cooperation between T cell lymphokines for induction of the nitric oxide synthase gene in murine peritoneal macrophages. J. Immunol. (1993) 151(1):322-329.
130. GROVER VS, SHARMA A, SINGH M: Role of nitric oxide in diabetes-induced attenuation of antinociceptive effect of morphine in mice. Eur. J. Pharmacol. (2000) 399(2-3):161-164.
131. BILFINGER TV, VOSSWINKEL JA, CADET P et al.: Direct assessment of diminished production of morphine stimulated NO by diabetic endothelium from saphenous vein. Acta Pharmacologica Sinica (2002) 23(2):97-102.
132. LEVY D, STRASSMAN AM: Modulation of durai nociceptor mechanosensitivity by the nitric oxide-cyclic GMP signaling cascade. J. Neurophysiol. (2004) 92(2):766-772.
133. XU JY, TSENG LF: Increase of nitric oxide by L-arginine potentiates beta-endorphin- but not mu-, delta- or kappa-opioid agonist-induced antinociception in the mouse. Eur. J. Pharmacol. (1993) 236(1):137-142.
134. KAWABATA A, UMEDA N, TAKAGI H: L-arginine exerts a dual role in nociceptive processing in the brain: involvement of the kyotorphin-Met- enkephalin pathway and NO-cyclic GMP pathway. Br. J. Pharmacol. (1993) 109(1):73-79.
135. MELLER ST, DENNIS BJ: Efferent projections of the periaqueductal gray in the rabbit. Neuroscience (1991) 40(1):191-216.
136. IWAMOTO ET, MARION L: Pharmacological evidence that nitric oxide mediates the antinociception produced by muscarinic agonists in the rostral ventral medulla of rats. J. Pharmacol. Exp. Ther. (1994) 269(2):699-708.
137. MILLAN MJ: The induction of pain: an integrative review. Prog. Neurobiol. (1999) 57(1):1-164.
138. LEI SZ, PAN ZH, AGGARWAL SK et al.: Effect of nitric oxide production on the redox modulatory site of the NMDA receptor-channel complex. Neuron (1992) 8(6):1087-1099.
139. LIPTON SA, CHOI YB, PAN ZH et al.: A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitrosocompounds. Nature (1993) 364(6438):626-632.
140. CUNHA FQ, TEIXEIRA MM, FERREIRA SH: Pharmacological modulation of secondary mediator systems-cyclic AMP and cyclic GMP-on inflammatory hyperalgesia. Br. J Pharmacol. (1999) 127(3):671-678.
141. STEFANO GB, MAGAZINE HI: Nitric oxide autoregulation and its significance. Mod. Aspects Immunobiol. (2001) 1:182-186.
142. STEFANO GB, SALZET M, MAGAZINE HI, BILFINGER TV: Antagonist of LPS and IFN-γ induction of iNOS in human saphenous vein endothelium by morphine and anandamide by nitric oxide inhibition of adenylate cyclase. J. Cardiovasc. Pharmacol. (1998) 31:813-820.
143. MAKMAN MH, BILFINGER TV, STEFANO GB: Human granulocytes contain an opiate receptor mediating inhibition of cytokine-induced activation and chemotaxis. J. Immunol. (1995) 154:1323-1330.
144. NIETO-FERNANDEZFE, MATTOCKS DW, CAVANI F, SALZET M, STEFANO GB: Morphine coupling to invertebrate immunocyte nitric oxide release is dependent on intracellular calcium transients. Comp. Biochem. Physiol. (1999) 123(3):295-299.
145. STEFANO GB, HARTMAN A, BILFINGER TV et al.: Presence of the mu3 opiate receptor in endothelial cells: Coupling to nitric oxide production and vasodilation. J. Biol. Chem. (1995) 270(51):30290-30293.
146. CADET P: Mu opiate receptor subtypes. Med. Sci. Monit. (2004) 10(6):MS28-MS32.
147. MAGAZINE HI, LIU Y, BILFINGER TV, FRICCHIONE GL, STEFANO GB: Morphine-induced conformational changes in human monocytes, granulocytes, and endothelial cells and in invertebrate immunocytes and microglia are mediated by nitric oxide. J. Immunol. (1996) 156:4845-4850.
148. WELTERS ID, MENZEBACH A, GOUMON Y et al.: Morphine inhibits NF-κB nuclear binding in human neutrophils and monocytes by a nitric oxide dependent mechanism. Anesthesiol. (2000) 92(6):1677-1684.